Non-clinical Pharmacokinetic Behavior of Ginsenosides

Overview

Journal J Ginseng Res

Date 2019 Jul 17

PMID 31308806

Citations 30

Authors

Hyo-Joong Won

Hyun Il Kim

Taejun Park

Hyeongmin Kim

Kanghee Jo

Hyojin Jeon

Seo Jun Ha

Jung Min Hyun

Aeri Jeong

Jung Sik Kim

Ye Jin Park

Yun Ho Eo

Jaehwi Lee

Affiliations

Soon will be listed here.

Abstract

Ginsenosides, the major active ingredients of ginseng and other plants of the genus , have been used as natural medicines in the East for a long time; in addition, their popularity in the West has increased owing to their various beneficial pharmacological effects. There is therefore a wealth of literature regarding the pharmacological effects of ginsenosides. In contrast, there are few comprehensive studies that investigate their pharmacokinetic behaviors. This is because ginseng contains the complicated mixture of herbal materials as well as thousands of constituents with complex chemical properties, and ginsenosides undergo multiple biotransformation processes after administration. This is a significant issue as pharmacokinetic studies provide crucial data regarding the efficacy and safety of compounds. Moreover, there have been many difficulties in the development of the optimal dosage regimens of ginsenosides and the evaluation of their interactions with other drugs. Therefore, this review details the pharmacokinetic properties and profiles of ginsenosides determined in various animal models administered through different routes of administration. Such information is valuable for designing specialized delivery systems and determining optimal dosing strategies for ginsenosides.

Citing Articles

Ginsenoside Rg1 Regulates the Activation of Astrocytes Through lncRNA-Malat1/miR-124-3p/Lamc1 Axis Driving PI3K/AKT Signaling Pathway, Promoting the Repair of Spinal Cord Injury.

Zhu Y, Zou W, Sun B, Shen K, Xia F, Wang H CNS Neurosci Ther. 2024; 30(11):e70103.

PMID: 39491316 PMC: 11532020. DOI: 10.1111/cns.70103.

Preparation and evaluation of proliposomes formulation for enhancing the oral bioavailability of ginsenosides.

Nguyen D, Kim M, Baek M, Kang N, Kim D J Ginseng Res. 2024; 48(4):417-424.

PMID: 39036737 PMC: 11259707. DOI: 10.1016/j.jgr.2024.03.004.

Metabolism and drug interactions of Korean ginseng based on the pharmacokinetic properties of ginsenosides: Current status and future perspectives.

Park J J Ginseng Res. 2024; 48(3):253-265.

PMID: 38707645 PMC: 11068998. DOI: 10.1016/j.jgr.2024.02.003.

Therapeutic effect of notoginseng saponins before and after fermentation on blood deficiency rats.

Su W, Liang Z, Pan D, Zhang L, Zhang Y, Yuan T Exp Ther Med. 2024; 27(4):143.

PMID: 38476921 PMC: 10928825. DOI: 10.3892/etm.2024.12431.

Protopanaxadiol improves lupus nephritis by regulating the PTX3/MAPK/ERK1/2 pathway.

Li Z, Gan H, Ji K, Yang M, Pan T, Meng X J Nat Med. 2024; 78(3):474-487.

PMID: 38431911 DOI: 10.1007/s11418-023-01777-9.

References

Takino Y . [Studies on the pharmacodynamics of ginsenoside-Rg1, -Rb1 and -Rb2 in rats]. Yakugaku Zasshi. 1994; 114(8):550-64. View

Toutain P, Bousquet-Melou A . Plasma clearance. J Vet Pharmacol Ther. 2004; 27(6):415-25. DOI: 10.1111/j.1365-2885.2004.00605.x. View

Baek K, Yi Y, Son Y, Yoo S, Sung N, Kim Y . and anti-inflammatory activities of Korean Red Ginseng-derived components. J Ginseng Res. 2016; 40(4):437-444. PMC: 5052440. DOI: 10.1016/j.jgr.2016.08.003. View

Park J, Shin J, Jung J, Hyun J, Van Le T, Kim D . Anti-inflammatory mechanism of compound K in activated microglia and its neuroprotective effect on experimental stroke in mice. J Pharmacol Exp Ther. 2011; 341(1):59-67. DOI: 10.1124/jpet.111.189035. View

Qian T, Cai Z, Wong R, Mak N, Jiang Z . In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 816(1-2):223-32. DOI: 10.1016/j.jchromb.2004.11.036. View

Gu Y, Wang G, Sun J, Jia Y, Wang W, Xu M . Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. Food Chem Toxicol. 2009; 47(9):2257-68. DOI: 10.1016/j.fct.2009.06.013. View

Shi Y, Han B, Yu X, Qu S, Sui D . Ginsenoside Rb3 ameliorates myocardial ischemia-reperfusion injury in rats. Pharm Biol. 2011; 49(9):900-6. DOI: 10.3109/13880209.2011.554845. View

Kim S, Lee S, Yuk D, Moon D, Choi S, Kim Y . Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res. 2009; 32(5):755-65. DOI: 10.1007/s12272-009-1515-4. View

Li J, Shao Z, Xie J, Wang C, Ramachandran S, Yin J . The effects of ginsenoside Rb1 on JNK in oxidative injury in cardiomyocytes. Arch Pharm Res. 2012; 35(7):1259-67. PMC: 3415887. DOI: 10.1007/s12272-012-0717-3. View

10.

He C, Feng R, Sun Y, Chu S, Chen J, Ma C . Simultaneous quantification of ginsenoside Rg1 and its metabolites by HPLC-MS/MS: Rg1 excretion in rat bile, urine and feces. Acta Pharm Sin B. 2016; 6(6):593-599. PMC: 5071637. DOI: 10.1016/j.apsb.2016.05.001. View

11.

Joo K, Lee J, Jeon H, Park C, Hong D, Jeong H . Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method. J Pharm Biomed Anal. 2009; 51(1):278-83. DOI: 10.1016/j.jpba.2009.08.013. View

12.

Li L, Chen X, Li D, Zhong D . Identification of 20(S)-protopanaxadiol metabolites in human liver microsomes and human hepatocytes. Drug Metab Dispos. 2010; 39(3):472-83. DOI: 10.1124/dmd.110.036723. View

13.

Wang J, Qiao L, Li S, Yang G . Protective effect of ginsenoside Rb1 against lung injury induced by intestinal ischemia-reperfusion in rats. Molecules. 2013; 18(1):1214-26. PMC: 6270255. DOI: 10.3390/molecules18011214. View

14.

Hao K, Gong P, Sun S, Hao H, Wang G, Dai Y . Mechanism-based pharmacokinetic-pharmacodynamic modeling of the estrogen-like effect of ginsenoside Rb1 on neural 5-HT in ovariectomized mice. Eur J Pharm Sci. 2011; 44(1-2):117-26. DOI: 10.1016/j.ejps.2011.06.014. View

15.

Xie H, Wang G, Lv H, Sun R, Jiang X, Li H . Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharacokinetic study in dogs. Eur J Drug Metab Pharmacokinet. 2005; 30(1-2):63-7. DOI: 10.1007/BF03226409. View

16.

Lee S, Kim M, Ko S, Kim H, Leem K, Kim Y . Protective effect of ginsenoside Re on acute gastric mucosal lesion induced by compound 48/80. J Ginseng Res. 2014; 38(2):89-96. PMC: 3986637. DOI: 10.1016/j.jgr.2013.10.001. View

17.

Hou Y, Tsai Y, Lin Y, Chao J . Ginseng extract and ginsenoside Rb1 attenuate carbon tetrachloride-induced liver fibrosis in rats. BMC Complement Altern Med. 2014; 14:415. PMC: 4216840. DOI: 10.1186/1472-6882-14-415. View

18.

Cheng Y, Shen L, Zhang J . Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin. 2005; 26(2):143-9. DOI: 10.1111/j.1745-7254.2005.00034.x. View

19.

Kim H . Pharmacokinetics of ginsenoside Rb1 and its metabolite compound K after oral administration of Korean Red Ginseng extract. J Ginseng Res. 2013; 37(4):451-6. PMC: 3825860. DOI: 10.5142/jgr.2013.37.451. View

20.

Wei S, Li W, Yu Y, Yao F, A L, Lan X . Ginsenoside Compound K suppresses the hepatic gluconeogenesis via activating adenosine-5'monophosphate kinase: A study in vitro and in vivo. Life Sci. 2015; 139:8-15. DOI: 10.1016/j.lfs.2015.07.032. View